Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Pharmos receives grant to develop loteprednol/tobramycin combination product

July 19, 1996

FDA will review BioLon PMA

July 5, 1996

Allergan's Acular available on U.K. market

June 14, 1996

Xalatan approved for U.S. market

June 14, 1996

InSite Vision and Ciba Vision marketing agreement for sustained-release eyedrop formulation

June 7, 1996

Ofloxacin ophthalmic solution receives FDA approval

May 31, 1996

Carbonic anhydrase inhibitors from Alcon

May 31, 1996

Anti-VEGF oligonucleotides inhibit retinal neovascularization in preclinical model

May 17, 1996

SnET2 enters phase I/II for AMD indication

May 17, 1996

Pharmos, Bausch & Lomb expand Lotemax agreement

May 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...